Short Communication - (2023) Volume 13, Issue 5
Received: 04-Sep-2023, Manuscript No. jsmds-23-114931;
Editor assigned: 06-Sep-2023, Pre QC No. P-114931;
Reviewed: 18-Sep-2023, QC No. Q-114931;
Revised: 23-Sep-2023, Manuscript No. R-114931;
Published:
30-Sep-2023
, DOI: 10.37421/2161-0673.2023.13.333
Citation: Lupidi, Lisuna. “Exploring Anamorelin’s Metabolic
Effects on Athletes Hepatocytes Using LC-HRMS/MS.” J Sports Med Doping
Stud 13 (2023): 333.
Copyright: © 2023 Lupidi L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Anamorelin, a Growth Hormone Secretagogue Receptor 1a (GHSR1a) agonist, has garnered attention in recent years due to its potential misuse in the realm of sports. Athletes may seek to exploit its pharmacological properties to gain an unfair advantage, primarily by promoting muscle growth and enhancing performance [1]. Understanding the metabolic effects of anamorelin on hepatocytes is crucial in shedding light on its mechanisms of action and potential for misuse. In this study, we aim to explore the impact of anamorelin on human hepatocytes, employing Liquid Chromatography-High-Resolution Mass Spectrometry (LC-HRMS/MS) to analyse the metabolic changes induced by this compound. By delving into the hepatic metabolism of anamorelin, we hope to provide valuable insights into its potential risks and benefits in the context of athletic performance enhancement [2].
The study involved the utilization of primary human hepatocytes obtained from a well-established in vitro model. These hepatocytes were exposed to varying concentrations of anamorelin, replicating conditions that athletes may encounter when misusing the compound [3]. Following exposure, we meticulously examined the metabolic profile of the hepatocytes using LCHRMS/ MS, a state-of-the-art analytical technique known for its precision and sensitivity in detecting molecular changes Our analysis focused on identifying alterations in the expression of metabolites associated with key hepatic processes such as energy metabolism, lipid metabolism and detoxification pathways. By comparing the metabolic profiles of hepatocytes treated with anamorelin to control groups, we aimed to pinpoint any significant deviations that could indicate potential risks or advantages of using this compound in a sporting context [4,5].
The findings of our study unveil a complex web of metabolic effects induced by anamorelin in athletes' hepatocytes. These effects extend beyond mere muscle growth stimulation, delving into intricate changes within the liver's metabolic machinery. Notably, we observed significant alterations in energy utilization patterns, lipid metabolism and detoxification pathways in response to anamorelin exposure. This study emphasizes the multifaceted nature of anamorelin's impact on athletes' physiology, underlining both its potential benefits in terms of performance enhancement and the potential health risks that may accompany its misuse. As such, it underscores the importance of informed decision-making among athletes and robust monitoring by sports authorities and healthcare professionals. In conclusion, our research underscores the critical need for continued investigation into the metabolic effects of anamorelin and similar compounds, aiming to strike a balance between the pursuit of excellence in sports and the preservation of athletes' health and integrity. Such efforts are pivotal in ensuring that the world of sports remains a fair and safe arena for all athletes.
None.
There are no conflicts of interest by author.
Journal of Sports Medicine & Doping Studies received 1022 citations as per Google Scholar report
